Zura Bio Widens Third-Quarter Loss as Tibulizumab Trials Finish

The Tip Desk · November 10, 2026 · 3 min read

The clinical-stage biotech posted a $25.8 million net loss, or $0.20 a share, and held $187.7 million in cash as both Phase 2 tibulizumab studies completed enrollment.

Zura Bio Limited (ZURA), a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases, reported a net loss of $25.8 million, or $0.20 a share, for the third quarter ended September 30, 2026, compared with a loss of $18.0 million, or $0.21 a share, a year earlier.

Research and development expenses rose to $19.5 million from $11.9 million in the same period of 2025. The company said the increase was primarily driven by continued execution of its Phase 2 tibulizumab clinical programs and start-up activities for NEXUS-PMR. General and administrative expenses were $9.3 million, versus $7.6 million a year earlier, which the company attributed primarily to higher professional fees.

Cash and cash equivalents were $187.7 million as of September 30, 2026, down from $205.1 million as of June 30, 2026. Zura said it expects that cash to fund planned operations through at least the end of 2028.

The quarter’s operating story was the completion of enrollment in both ongoing Phase 2 studies of tibulizumab, a bispecific antibody designed to neutralize interleukin-17 and B-cell activating factor, and the FDA clearance of a third Phase 2 program. TibuSHIELD in hidradenitis suppurativa finished enrollment in June 2026 with 247 participants, exceeding its target. Topline data remained on track for the fourth quarter of 2026 and will include the primary endpoint, percent change from baseline in total abscess and inflammatory nodule count at Week 16, as well as the proportion of participants achieving HiSCR50 or HiSCR75.

TibuSURE in early diffuse cutaneous systemic sclerosis completed enrollment in July 2026 with 91 participants, also exceeding its target. Topline data remained on track for the first half of 2027 and will include the primary endpoint, change from baseline in modified Rodnan Skin Score at Week 24, as well as measures of lung involvement.

NEXUS-PMR, a Phase 2 study evaluating tibulizumab in polymyalgia rheumatica, had been cleared by the U.S. Food and Drug Administration to proceed under an Investigational New Drug application and remained on track to initiate by year-end 2026. In the second-quarter update the company had selected PMR as the third indication and said it had received constructive FDA feedback on the proposed strategy.

Chief Executive Officer Sandeep Kulkarni said the team continues to execute efficiently on the development plan for tibulizumab and that the company is on track to report topline results from TibuSHIELD later in the quarter, followed by TibuSURE in the first half of 2027. He said Zura will be starting NEXUS-PMR by end of year and that cash runway is sufficient to deliver results from all three studies.

Tibulizumab remains an investigational compound and has not been approved for marketing by the FDA or any other regulatory authority. In addition to tibulizumab, Zura said it is continuing its evaluation of potential development approaches for torudokimab and crebankitug, informed by current clinical and translational evidence and ongoing assessment of the competitive landscape.

The company described itself as a clinical-stage, multi-asset immunology company developing dual-pathway antibodies. Its pipeline includes product candidates designed to target mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience. Tibulizumab is the lead candidate in two Phase 2 studies, with NEXUS-PMR planned as a third. Torudokimab and crebankitug have completed Phase 1/1b studies and are being evaluated across a range of autoimmune and inflammatory conditions.